IR 05000232/2014001: Difference between revisions
StriderTol (talk | contribs) (StriderTol Bot change) |
StriderTol (talk | contribs) (StriderTol Bot change) |
||
(2 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
{{Adams | {{Adams | ||
| number = | | number = ML22095A285 | ||
| issue date = 04/ | | issue date = 04/05/2022 | ||
| title = | | title = 627275-Amendment 24 License 50-23214-01/030-20372 for Diagnostic Health Center of Anchorage, LLC | ||
| author name = | | author name = Hanson L | ||
| author affiliation = NRC | | author affiliation = NRC/RGN-IV/DNMS | ||
| addressee name = | | addressee name = | ||
| addressee affiliation = | | addressee affiliation = NRC/Document Control Desk | ||
| docket = 03020372 | | docket = 03020372 | ||
| license number = | | license number = 50-23214-01 | ||
| contact person = | | contact person = | ||
| | | case reference number = License-627275-165144 | ||
| document type = License-Approval for MATL Byproduct License (Amend/Renewal/New) DKT 30, 40, 70 | |||
| document type = | |||
| page count = 1 | | page count = 1 | ||
}} | }} | ||
Line 19: | Line 18: | ||
=Text= | =Text= | ||
{{#Wiki_filter: | {{#Wiki_filter:NRC FORM 374 PAGE 1 OF 3 PAGES U.S. NUCLEAR REGULATORY COMMISSION Amendment No. 24 MATERIALS LICENSE Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) | ||
and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified belo Licensee In accordance with letter dated 4. Expiration Date: March 31, 2025 July 6, 2021 1. Diagnostic Health Center of Anchorage, LLC A wholly owned subsidiary of Alliance HealthCare Services 5. Docket No.: 030-20372 2. 4100 Lake Otis Parkway #102 3. License No.: 50-23214-01 is Reference No.: | |||
Anchorage, AK 99508 amended in its entirety to read as follows: Byproduct, source, Chemical and/or physical form Maximum amount that licensee Authorized use and/or special nuclear may possess at any one time material under this license Any byproduct material Any As Needed For use in uptake, dilution and permitted by 10 CFR excretion studies permitted by 10 CFR 35.100 35.10 Any byproduct material Any As Needed For use in imaging and localization permitted by 10 CFR studies permitted by 10 CFR 35.20 .200 Iodine-131 Any millicuries total Any sodium iodide Iodine-131 use permitted by 10 CFR 35.300 for which the patient can be released under the provisions of 10 CFR 35.7 Any byproduct material Prepackaged Kits millicuries total For use in in-vitro studie permitted by 10 CFR 31.11 | |||
NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSION PAGE 2 OF 3 PAGES License No.: 50-23214-01 Docket or Reference No.: | |||
MATERIALS LICENSE 030-20372 SUPPLEMENTARY SHEET Amendment No. 24 CONDITIONS 10. Licensed material may be used only at the licensees facilities located at Lake Otis Medical Plaza, 4100 Lake Otis Parkway #102, Anchorage, Alaska. | |||
Anchorage, Alaska | |||
11. The Radiation Safety Officer for this license is Kay Kassel, MS, CNMT. | |||
12. Licensed material shall only be used by, or under the supervision of: | |||
A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.1 B. The following individuals are authorized users for the material and medical uses as indicated: | |||
Authorized Users Material and Use Marc R. Beck, .100; 35.200; Oral administration of sodium iodide I-131; 31.11 Robert L. Bridges, .100; 35.200; Oral administration of sodium iodide I-131; 31.11 13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assuranc NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSION PAGE 3 OF 3 PAGES License No.: 50-23214-01 Docket or Reference No.: | |||
MATERIALS LICENSE 030-20372 SUPPLEMENTARY SHEET Amendment No. 24 14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensees ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commissions regulations shall govern unless the statements, representations, and procedures in the licensees application and correspondence are more restrictive than the regulation A. Application dated October 20, 2014 (ML14336A723) | |||
B. Letter dated February 16, 2015 with enclosures (ML15061A178) | |||
C. Letter dated July 6, 2021 (ML21196A052) | |||
FOR THE U.S. NUCLEAR REGULATORY COMMISSION Digitally signed by Latischa Latischa M. Hanson Hanson April 5, 2022 Date: 2022.04.05 19:20:39 -05'00' | |||
Date: By: | |||
Latischa M. Hanson Region IV ML22073A267 | |||
}} | }} |
Latest revision as of 02:43, 11 May 2022
ML22095A285 | |
Person / Time | |
---|---|
Site: | 05000232, 03020372 |
Issue date: | 04/05/2022 |
From: | Latischa Hanson Division of Nuclear Materials Safety IV |
To: | Document Control Desk |
References | |
License-627275-165144 | |
Download: ML22095A285 (1) | |
Text
NRC FORM 374 PAGE 1 OF 3 PAGES U.S. NUCLEAR REGULATORY COMMISSION Amendment No. 24 MATERIALS LICENSE Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s)
and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified belo Licensee In accordance with letter dated 4. Expiration Date: March 31, 2025 July 6, 2021 1. Diagnostic Health Center of Anchorage, LLC A wholly owned subsidiary of Alliance HealthCare Services 5. Docket No.: 030-20372 2. 4100 Lake Otis Parkway #102 3. License No.: 50-23214-01 is Reference No.:
Anchorage, AK 99508 amended in its entirety to read as follows: Byproduct, source, Chemical and/or physical form Maximum amount that licensee Authorized use and/or special nuclear may possess at any one time material under this license Any byproduct material Any As Needed For use in uptake, dilution and permitted by 10 CFR excretion studies permitted by 10 CFR 35.100 35.10 Any byproduct material Any As Needed For use in imaging and localization permitted by 10 CFR studies permitted by 10 CFR 35.20 .200 Iodine-131 Any millicuries total Any sodium iodide Iodine-131 use permitted by 10 CFR 35.300 for which the patient can be released under the provisions of 10 CFR 35.7 Any byproduct material Prepackaged Kits millicuries total For use in in-vitro studie permitted by 10 CFR 31.11
NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSION PAGE 2 OF 3 PAGES License No.: 50-23214-01 Docket or Reference No.:
MATERIALS LICENSE 030-20372 SUPPLEMENTARY SHEET Amendment No. 24 CONDITIONS 10. Licensed material may be used only at the licensees facilities located at Lake Otis Medical Plaza, 4100 Lake Otis Parkway #102, Anchorage, Alaska.
11. The Radiation Safety Officer for this license is Kay Kassel, MS, CNMT.
12. Licensed material shall only be used by, or under the supervision of:
A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.1 B. The following individuals are authorized users for the material and medical uses as indicated:
Authorized Users Material and Use Marc R. Beck, .100; 35.200; Oral administration of sodium iodide I-131; 31.11 Robert L. Bridges, .100; 35.200; Oral administration of sodium iodide I-131; 31.11 13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assuranc NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSION PAGE 3 OF 3 PAGES License No.: 50-23214-01 Docket or Reference No.:
MATERIALS LICENSE 030-20372 SUPPLEMENTARY SHEET Amendment No. 24 14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensees ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commissions regulations shall govern unless the statements, representations, and procedures in the licensees application and correspondence are more restrictive than the regulation A. Application dated October 20, 2014 (ML14336A723)
B. Letter dated February 16, 2015 with enclosures (ML15061A178)
C. Letter dated July 6, 2021 (ML21196A052)
FOR THE U.S. NUCLEAR REGULATORY COMMISSION Digitally signed by Latischa Latischa M. Hanson Hanson April 5, 2022 Date: 2022.04.05 19:20:39 -05'00'
Date: By:
Latischa M. Hanson Region IV ML22073A267